FDA's biologics chief stresses need for vaccine transmission data
Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the FDA's Center for Biologics Evaluation ...
Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the FDA's Center for Biologics Evaluation ...
